Bailard’s CASI Pharmaceuticals CASI Stock Holding History

Bailard’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-31,530	Closed	-$90K	–	679
2022 Q2	$90K	Buy	31,530 +29,020	+1,156%	+$126K	﹤0.01%	661
2022 Q1	$20K	Buy	+2,510	New	+$19.7K	﹤0.01%	714
2021 Q3	–	Sell	-4,040	Closed	-$63K	–	716
2021 Q2	$63K	Buy	+4,040	New	+$68K	﹤0.01%	698

Other funds holding CASI

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bailard's CASI Position: Q3 2022 in Review

Bailard sold out of CASI Pharmaceuticals (CASI) in Q3 2022, closing a stake of 31,530 shares — an estimated $90K sold.

Bailard first reported a position in CASI in Q2 2021 and held it in 3 quarters. The position peaked at $90K in Q2 2022. 24 funds tracked by Wall St. Rank hold CASI as of Q3 2022.

Bailard reported no remaining CASI Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Bailard sold 31,530 CASI Pharmaceuticals shares in Q3 2022, an estimated $90K.
Bailard first reported a position in CASI Pharmaceuticals in Q2 2021 and held it in 3 quarters.
Bailard's CASI Pharmaceuticals position peaked at $90K in Q2 2022.
24 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.